RENE.L Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (5 Feb 2024 @ 09:22):

Stats
Today's Volume	530.00
Average Volume	35 233.00
Market Cap	1.93M
EPS	£0 ( 2023-11-07 )
Next earnings date	( £0 ) 2024-05-22
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-0.380
ATR14	£0.290 (859.26%)

Volume Correlation

Long: 0.09 (neutral)

Short: 0.00 (neutral)

Signal:(12.475) Neutral

ReNeuron Group PLC Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ReNeuron Group PLC Correlation - Currency/Commodity

-0.26
( neutral )

-0.41
( neutral )

0.58
( weak )

0.65
( weak )

-0.45
( neutral )

0.10
( neutral )

ReNeuron Group PLC Financials

Annual	2022
Revenue:	£530 000
Gross Profit:	£-3.93M (-742.08 %)
EPS:	£-0.0947

Q2	2023
Revenue:	£157 000
Gross Profit:	£28 000.00 (17.83 %)
EPS:	£-0.0497

Q1	2023
Revenue:	£78 500.00
Gross Profit:	£78 500.00 (100.00 %)
EPS:	£-0.0250

Q4	2022
Revenue:	£92 000.00
Gross Profit:	£-43 000.00 (-46.74 %)
EPS:	£-0.0390

Financial Reports:

No articles found.

ReNeuron Group PLC

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in the partnering stage in china and outside china for treating stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom.